Literature DB >> 21166698

De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway.

Raphaela Fritsche-Guenther1, Aurelia Noske, Ute Ungethüm, Ralf-Jürgen Kuban, Peter M Schlag, Per-Ulf Tunn, Janine Karle, Veit Krenn, Manfred Dietel, Christine Sers.   

Abstract

AIMS: In osteosarcoma patients the development of metastases, often to the lungs, is the most frequent cause of death. The aim of this study was to elucidate the molecular mechanisms governing osteosarcoma development and dissemination and, thereby, to identify possible novel drug targets for improved treatment. METHODS AND
RESULTS: Osteosarcoma samples were characterized using genome-wide microarrays: increased expression of the EphA2 receptor and its ligand EFNA1 was detected. In addition, increased expression of EFNB1, EFNB3 and EphA3 was suggested. Immunohistochemistry revealed an absence of EphA2 in normal bone, and de novo expression in osteosarcomas. EFNA1 was expressed in normal bone, but was significantly elevated in tumours. Further in vitro investigations on the functional role of EphA2 and EFNA1 showed that EFNA1 ligand binding induced increased tyrosine phosphorylation, receptor degradation and downstream mitogen-activated protein kinase (MAPK) activation. Interference with the MAPK pathway unravelled a potential autoregulatory loop governing mainly EFNA1 expression via the same pathway.
CONCLUSION: Upregulation and de novo expression of ephrins in osteosarcomas are involved in oncogenic signalling and thus might stimulate osteosarcoma metastasis.
© 2010 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21166698     DOI: 10.1111/j.1365-2559.2010.03713.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  32 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

2.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 3.  Membrane-mediated regulation of vascular identity.

Authors:  Takuya Hashimoto; Masayuki Tsuneki; Trenton R Foster; Jeans M Santana; Hualong Bai; Mo Wang; Haidi Hu; Jesse J Hanisch; Alan Dardik
Journal:  Birth Defects Res C Embryo Today       Date:  2016-03-17

4.  PLEK2 promotes osteosarcoma tumorigenesis and metastasis by activating the PI3K/AKT signaling pathway.

Authors:  Yang Liu; Siting Yang; Feng Wang; Zheng Zhou; Wenjing Xu; Jingjing Xie; Linhui Qiao; Yanglin Gu
Journal:  Oncol Lett       Date:  2021-05-18       Impact factor: 2.967

Review 5.  Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases.

Authors:  Koichi Matsuo; Natsuko Otaki
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

6.  Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Authors:  Vaibhav Saini; Curtis D Hose; Anne Monks; Kunio Nagashima; Bingnan Han; Dianne L Newton; Angelena Millione; Jalpa Shah; Melinda G Hollingshead; Karen M Hite; Mark W Burkett; Rene M Delosh; Thomas E Silvers; Dominic A Scudiero; Robert H Shoemaker
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

7.  Integrative Analysis of MicroRNA and mRNA Sequencing Data Identifies Novel Candidate Genes and Pathways for Developmental Dysplasia of Hip.

Authors:  Bolun Cheng; Yumeng Jia; Yan Wen; Weikun Hou; Ke Xu; Chujun Liang; Shiqiang Cheng; Li Liu; Xiaomeng Chu; Jing Ye; Yao Yao; Feng Zhang; Peng Xu
Journal:  Cartilage       Date:  2021-02-01       Impact factor: 3.117

8.  Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.

Authors:  A N Rettew; E D Young; D C Lev; E S Kleinerman; F W Abdul-Karim; P J Getty; E M Greenfield
Journal:  Oncogenesis       Date:  2012-11-19       Impact factor: 7.485

9.  Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.

Authors:  Janne Nordberg; John Patrick Mpindi; Kristiina Iljin; Arto Tapio Pulliainen; Markku Kallajoki; Olli Kallioniemi; Klaus Elenius; Varpu Elenius
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

10.  Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours.

Authors:  Kenneth Hsu; Shiloh Middlemiss; Federica Saletta; Stephen Gottschalk; Geoffrey B McCowage; Belinda Kramer
Journal:  Cancer Gene Ther       Date:  2020-09-01       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.